BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34681879)

  • 1. Identification of Tumor Antigens in Ovarian Cancers Using Local and Circulating Tumor-Specific Antibodies.
    Da Gama Duarte J; Quigley LT; Young AR; Hayashi M; Miyazawa M; Lopata A; Mancuso N; Mikami M; Behren A; Meeusen E
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early pregnancy sex steroids and maternal risk of epithelial ovarian cancer.
    Schock H; Surcel HM; Zeleniuch-Jacquotte A; Grankvist K; Lakso HÅ; Fortner RT; Kaaks R; Pukkala E; Lehtinen M; Toniolo P; Lundin E
    Endocr Relat Cancer; 2014; 21(6):831-44. PubMed ID: 25270324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoantibody biomarkers for the detection of serous ovarian cancer.
    Katchman BA; Chowell D; Wallstrom G; Vitonis AF; LaBaer J; Cramer DW; Anderson KS
    Gynecol Oncol; 2017 Jul; 146(1):129-136. PubMed ID: 28427776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated serum 8-OHdG is associated with poor prognosis in epithelial ovarian cancer.
    Pylväs M; Puistola U; Laatio L; Kauppila S; Karihtala P
    Anticancer Res; 2011 Apr; 31(4):1411-5. PubMed ID: 21508394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer.
    Simmons AR; Fourkala EO; Gentry-Maharaj A; Ryan A; Sutton MN; Baggerly K; Zheng H; Lu KH; Jacobs I; Skates S; Menon U; Bast RC
    Cancer Prev Res (Phila); 2019 Jun; 12(6):391-400. PubMed ID: 30967390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of phosphatidylserine-positive exosomes as a diagnostic marker for ovarian malignancies: a proof of concept study.
    Lea J; Sharma R; Yang F; Zhu H; Ward ES; Schroit AJ
    Oncotarget; 2017 Feb; 8(9):14395-14407. PubMed ID: 28122335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LyGDI is a promising biomarker for ovarian cancer.
    Zhen H; Yang S; Wu H; Wang S; Lv J; Ma L; Zhang X
    Int J Gynecol Cancer; 2010 Apr; 20(3):316-22. PubMed ID: 20375790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating prolactin levels and risk of epithelial ovarian cancer.
    Clendenen TV; Arslan AA; Lokshin AE; Liu M; Lundin E; Koenig KL; Berrino F; Hallmans G; Idahl A; Krogh V; Lukanova A; Marrangoni A; Muti P; Nolen BM; Ohlson N; Shore RE; Sieri S; Zeleniuch-Jacquotte A
    Cancer Causes Control; 2013 Apr; 24(4):741-8. PubMed ID: 23378139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer.
    Asher V; Lee J; Innamaa A; Bali A
    Clin Transl Oncol; 2011 Jul; 13(7):499-503. PubMed ID: 21775277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic Performance of Serum Human Epididymis Protein 4 (HE4) for Prediction of Malignancy in Ovarian Masses.
    Dewan R; Dewan A; Jindal M; Bhardawaj M
    Asian Pac J Cancer Prev; 2019 Apr; 20(4):1103-1108. PubMed ID: 31030480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The risk of malignancy index (RMI) in diagnosis of ovarian malignancy.
    Moolthiya W; Yuenyao P
    Asian Pac J Cancer Prev; 2009; 10(5):865-8. PubMed ID: 20162854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and predictive relevance of CA-125 at primary surgery of ovarian cancer.
    Mury D; Woelber L; Jung S; Eulenburg C; Choschzick M; Witzel I; Schwarz J; Jaenicke F; Mahner S
    J Cancer Res Clin Oncol; 2011 Jul; 137(7):1131-7. PubMed ID: 21344262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of serum autoantibodies to tumor suppressor gene p53 with a new enzyme-linked immunosorbent assay in patients with ovarian cancer.
    Marx D; Frey M; Zentgraf H; Adelssen G; Schauer A; Kuhn W; Meden H
    Cancer Detect Prev; 2001; 25(2):117-22. PubMed ID: 11341346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer.
    Budiu RA; Mantia-Smaldone G; Elishaev E; Chu T; Thaller J; McCabe K; Lenzner D; Edwards RP; Vlad AM
    Cancer Immunol Immunother; 2011 Jul; 60(7):975-84. PubMed ID: 21461842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
    S SK; Swamy SN; Premalatha CS; Pallavi VR; Gawari R
    Asian Pac J Cancer Prev; 2019 Oct; 20(10):3001-3005. PubMed ID: 31653147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using protein microarray to identify and evaluate autoantibodies to tumor-associated antigens in ovarian cancer.
    Ma Y; Wang X; Qiu C; Qin J; Wang K; Sun G; Jiang D; Li J; Wang L; Shi J; Wang P; Ye H; Dai L; Jiang BH; Zhang J
    Cancer Sci; 2021 Feb; 112(2):537-549. PubMed ID: 33185955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoantibody profiling to identify biomarkers of key pathogenic pathways in mucinous ovarian cancer.
    Tang L; Yang J; Ng SK; Rodriguez N; Choi PW; Vitonis A; Wang K; McLachlan GJ; Caiazzo RJ; Liu BC; Welch WR; Cramer DW; Berkowitz RS; Ng SW
    Eur J Cancer; 2010 Jan; 46(1):170-9. PubMed ID: 19926475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical validation of multiple biomarkers suspension array technology for ovarian cancer].
    Zhao BB; Yang ZJ; Wang Q; Pan ZM; Zhang W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):11-19. PubMed ID: 28190310
    [No Abstract]   [Full Text] [Related]  

  • 19. Inflammatory Markers and Risk of Epithelial Ovarian Cancer by Tumor Subtypes: The EPIC Cohort.
    Ose J; Schock H; Tjønneland A; Hansen L; Overvad K; Dossus L; Clavel-Chapelon F; Baglietto L; Boeing H; Trichopolou A; Benetou V; Lagiou P; Masala G; Tagliabue G; Tumino R; Sacerdote C; Mattiello A; Bueno-de-Mesquita HB; Peeters PH; Onland-Moret NC; Weiderpass E; Gram IT; Sánchez S; Obon-Santacana M; Sànchez-Pérez MJ; Larrañaga N; Castaño JM; Ardanaz E; Brändstedt J; Lundin E; Idahl A; Travis RC; Khaw KT; Rinaldi S; Romieu I; Merritt MA; Gunter MJ; Riboli E; Kaaks R; Fortner RT
    Cancer Epidemiol Biomarkers Prev; 2015 Jun; 24(6):951-61. PubMed ID: 25855626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated leukocyte cell adhesion molecule soluble form: a potential biomarker of epithelial ovarian cancer is increased in type II tumors.
    Carbotti G; Orengo AM; Mezzanzanica D; Bagnoli M; Brizzolara A; Emionite L; Puppo A; Centurioni MG; Bruzzone M; Marroni P; Rossello A; Canevari S; Ferrini S; Fabbi M
    Int J Cancer; 2013 Jun; 132(11):2597-605. PubMed ID: 23169448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.